Healthcare provider profile · identity verified

Kavitha Bhagavatula, MD

Internal Medicine · WESTLAND, MI · NPI 1346277647

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	325	106
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	201	32
Amlodipine Besylate	Amlodipine Besylate	160	58
Lisinopril	Lisinopril	158	54
Metformin Hcl	Metformin Hcl	127	50
Levothyroxine Sodium	Levothyroxine Sodium	124	41
Gabapentin	Gabapentin	123	45
Losartan Potassium	Losartan Potassium	101	34
Metoprolol Tartrate	Metoprolol Tartrate	91	37
Metoprolol Succinate	Metoprolol Succinate	90	40
Albuterol Sulfate Hfa	Albuterol Sulfate	68	25
Alprazolam	Alprazolam	66	suppressed
Furosemide	Furosemide	65	25
Omeprazole	Omeprazole	63	29
Ozempic	Semaglutide	55	12
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	53	14
Hydrochlorothiazide	Hydrochlorothiazide	53	14
Hydralazine Hcl	Hydralazine Hcl	51	14
Simvastatin	Simvastatin	51	19
Rosuvastatin Calcium	Rosuvastatin Calcium	48	14
Allopurinol	Allopurinol	45	15
Baclofen	Baclofen	44	suppressed
Trulicity	Dulaglutide	44	suppressed
Oxycodone Hcl	Oxycodone Hcl	41	suppressed
Carvedilol	Carvedilol	39	17
Glipizide	Glipizide	39	13
Pantoprazole Sodium	Pantoprazole Sodium	38	17
Alendronate Sodium	Alendronate Sodium	37	suppressed
Tramadol Hcl	Tramadol Hcl	37	suppressed
Clopidogrel	Clopidogrel Bisulfate	35	12
Potassium Chloride	Potassium Chloride	33	11
Trazodone Hcl	Trazodone Hcl	33	suppressed
Montelukast Sodium	Montelukast Sodium	31	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	31	suppressed
Atenolol	Atenolol	30	suppressed
Prednisone	Prednisone	29	26
Tamsulosin Hcl	Tamsulosin Hcl	29	11
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Sertraline Hcl	Sertraline Hcl	27	11
Glimepiride	Glimepiride	26	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	24	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	24	11
Ventolin Hfa	Albuterol Sulfate	24	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	23	suppressed
Famotidine	Famotidine	23	11
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Clonazepam	Clonazepam	21	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	20	suppressed
Eliquis	Apixaban	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Meloxicam	Meloxicam	19	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	18	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Duloxetine Hcl	Duloxetine Hcl	17	suppressed
Ezetimibe	Ezetimibe	17	suppressed
Januvia	Sitagliptin Phosphate	17	suppressed
Diazepam	Diazepam	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Jardiance	Empagliflozin	15	suppressed
Valsartan	Valsartan	15	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	12	suppressed
Temazepam	Temazepam	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Amoxicillin	Amoxicillin	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Mupirocin	Mupirocin	11	suppressed
Spironolactone	Spironolactone	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error